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Summary
Background Sepsis continues to be a major cause of death, disability, and health-care expenditure worldwide. Despite 
evidence suggesting that host genetics can inﬂ uence sepsis outcomes, no speciﬁ c loci have yet been convincingly 
replicated. The aim of this study was to identify genetic variants that inﬂ uence sepsis survival.
Methods We did a genome-wide association study in three independent cohorts of white adult patients admitted to 
intensive care units with sepsis, severe sepsis, or septic shock (as deﬁ ned by the International Consensus Criteria) 
due to pneumonia or intra-abdominal infection (cohorts 1–3, n=2534 patients). The primary outcome was 28 day 
survival. Results for the cohort of patients with sepsis due to pneumonia were combined in a meta-analysis of 
1553 patients from all three cohorts, of whom 359 died within 28 days of admission to the intensive-care unit. The 
most signiﬁ cantly associated single nucleotide polymorphisms (SNPs) were genotyped in a further 538 white patients 
with sepsis due to pneumonia (cohort 4), of whom 106 died.
Findings In the genome-wide meta-analysis of three independent pneumonia cohorts (cohorts 1–3), common variants in 
the FER gene were strongly associated with survival (p=9·7 × 10–⁸). Further genotyping of the top associated SNP 
(rs4957796) in the additional cohort (cohort 4) resulted in a combined p value of 5·6 × 10–⁸ (odds ratio 0·56, 95% CI 
0·45–0·69). In a time-to-event analysis, each allele reduced the mortality over 28 days by 44% (hazard ratio for death 
0·56, 95% CI 0·45–0·69; likelihood ratio test p=3·4 × 10–⁹, after adjustment for age and stratiﬁ cation by cohort). Mortality 
was 9·5% in patients carrying the CC genotype, 15·2% in those carrying the TC genotype, and 25·3% in those carrying 
the TT genotype. No signiﬁ cant genetic associations were identiﬁ ed when patients with sepsis due to pneumonia and 
intra-abdominal infection were combined.
Interpretation We have identiﬁ ed common variants in the FER gene that associate with a reduced risk of death from 
sepsis due to pneumonia. The FER gene and associated molecular pathways are potential novel targets for therapy or 
prevention and candidates for the development of biomarkers for risk stratiﬁ cation.
Funding European Commission and the Wellcome Trust.
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Introduction
Despite advances in the treatment and prevention of 
infectious diseases, the incidence of sepsis is rising.1–3 
Mortality rates for sepsis remain unacceptably high at 
around 20–30%,2–5 and the eﬀ ect on health-care 
expenditure and resource use has been substantial.6,7 
Moreover, for those who survive the acute illness, the risk 
of death is increased for up to 5 years after the septic 
episode8,9 and quality of life is signiﬁ cantly impaired.10
Attempts to reduce mortality in patients with severe 
sepsis by modulating the host response have proved 
disappointing, partly because of poor understanding of 
the complex mechanisms that regulate innate immunity 
and the inﬂ ammatory cascade.11 Furthermore, such 
interventions are often delayed, and have usually been 
applied unselectively to heterogeneous groups of patients, 
without considering the potential inﬂ uence of host 
genetic diversity on response to treatment. Genomics has 
the potential to substantially advance our understanding 
of the key biological pathways implicated in human 
disease, and to suggest new targets for treatment or 
prevention.12 Additionally, characterisation of genetic 
variants associated with outcome from sepsis could 
enable us to identify those at high risk who might beneﬁ t 
from more aggressive interventions or from speciﬁ c, 
individually targeted, early, or pre-emptive measures.
More than two decades ago a landmark study13 
reported that adopted children had a 5·8 fold increased 
risk of death from infectious disease if one of their 
biological parents had died prematurely from infection, 
with most deaths being due to overwhelming bacterial 
infection.13 Although the role of the genetic proﬁ le of a 
host in determining susceptibility to infectious disease 
is well established,14–16 so far the results of candidate 
Lancet Respir Med 2015; 
3: 53–60
Published Online
December 18, 2014
http://dx.doi.org/10.1016/
S2213-2600(14)70290-5
See Comment page 7
*These authors supervised this 
work equally
Wellcome Trust Centre for 
Human Genetics, University 
of Oxford, Oxford, UK 
(A Rautanen PhD, T C Mills DPhil, 
T Parks MB, S J Chapman DM, 
E E Davenport MBiochem, 
K S Elliott PhD, 
Prof J C Knight DPhil, 
Prof A V S Hill DPhil); Imperial 
College London, London, UK 
(A C Gordon MD, 
P A H Holloway PhD); John 
Radcliﬀ e Hospital, Oxford, UK 
(P Hutton PG Cert, 
C S Garrard MD); William Harvey 
Research Institute, Barts and 
The London School of Medicine 
Queen Mary University of 
London, London, UK 
(R Nuamah BSc, C Mein PhD, 
Prof C J Hinds FRCP, 
Prof M J Caulﬁ eld MD); 
Hospital Cochin, Paris, France 
(Prof J-D Chiche MD), School 
of Clinical and Experimental 
Medicine, University of 
Birmingham, Birmingham, UK 
(Prof J Bion MD); Institute of 
Human Genetics, Helmholtz 
Zentrum München, 
German Research Center 
for Environmental Health, 
Neuherberg, Germany 
(P Lichtner PhD, 
Prof T Meitinger MD); 
Technische Universität 
München, Institute of Human 
Genetics, Munich, Germany 
(Prof T Meitinger ); Institute for 
Medical Biometry, Informatics 
and Epidemiology (IMBIE) of 
the University of Bonn, Bonn, 
Germany (M Steﬀ ens MD, 
Prof T F Wienker MD); Jena 
University Hospital and Center 
for Sepsis Control and Care, 
Jena, Germany (F Bloos MD,
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
69
69
9 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
Articles
54 www.thelancet.com/respiratory   Vol 3   January 2015
gene-association studies of sepsis susceptibility and 
outcome have often been inconsistent,17–20 possibly in 
part because the populations studied have been small 
and heterogeneous.11
To overcome the limitations of previous studies, we 
have done a large-scale genome-wide association study 
(GWAS) in well deﬁ ned groups of patients with the 
objective of identifying genetic variations associated with 
sepsis survival.
Methods 
Study design and participants 
The initial GWAS was an observational cohort study 
done in white patients admitted to European intensive-
care units (ICUs) with sepsis, severe sepsis, or septic 
shock as previously deﬁ ned21 (see appendix for 
deﬁ nitions) due to community-acquired pneumonia or 
peritonitis (n=1525). Patients were recruited through the 
GenOSept (Genetics of Sepsis and Septic Shock in 
Europe) consortium from 143 centres across 16 European 
countries between Sept 1, 2005, and Oct 31, 2009. Once 
the European GenOSept study was closed, recruitment 
continued in the UK according to the same protocol as 
part of the GAinS (Genomic Advances in Sepsis) study. 
We used a cohort of patients from the GAinS study with 
sepsis due to pneumonia (n=241; recruited until July 31, 
2011) to supplement the GenOSept GWAS (n=1525). All 
patients with pneumonia recruited to GenOSept/GAinS 
had sepsis due to community-acquired pneumonia. 
Ethics approval was granted either nationally, for 
individual centres, or both. Written, informed consent 
was obtained from all patients or a legal representative. 
The appendix shows a more detailed description of the 
patients and patient recruitment.
To increase the power of the analysis, the GenOSept/
GAinS discovery patient cohort (cohort 1) was 
supplemented by two independent, previously described 
cohorts of white patients with sepsis who were recruited 
within the Vasopressin in Septic Shock Trial (VASST)22 
(cohort 2) and the Human Activated Protein C Worldwide 
Evaluation in Severe Sepsis (PROWESS) trial23,24 
(cohort 3). In the VASST trial,22 patients with septic shock 
were recruited between July 1, 2001, and April 30, 2006, 
and randomly assigned  to receive either low-dose 
vasopressin or norepinephrine. In the GWAS analysis, 
we included patients in whom the lung or abdomen had 
been identiﬁ ed as the source of infection from both 
treatment groups, because the primary outcome of 
28 day survival did not diﬀ er between those treatment 
groups. In the PROWESS trial,23,24 patients with severe 
sepsis were recruited between July 1, 1998, and June 30, 
2000, and treated with human recombinant activated 
protein C or placebo. We included in our analysis only 
the patients from the placebo group of the trial in whom 
the lung or abdomen had been identiﬁ ed as the source of 
infection. The type of pneumonia (community-acquired, 
hospital-acquired, or ventilator-associated pneumonia) 
was not speciﬁ ed for patients recruited to VASST or 
PROWESS, although most patients would have had 
community-acquired pneumonia rather than hospital-
acquired or ventilator-associated pneumonia.25
An additional cohort (cohort 4) included patients 
recruited into the UK GAinS study with sepsis due to 
community-acquired pneumonia or peritonitis up to 
Jan 31, 2013, who had not been genome-wide genotyped 
(n=1002).
Figure 1 shows patient cohorts, sample numbers, 
genotyping, and analysis. The table shows patient 
characteristics for all these cohorts.
Procedures
Because the number of patients with sepsis due to intra-
abdominal infections was too small for an adequately 
powered GWAS, the analysis presented here is for 
survival in patients with sepsis due to pneumonia. 
We used diﬀ erent genome-wide single nucleotide 
polymorphism (SNP) arrays to genotype the separate 
sample collections. We applied stringent measures of 
quality control to remove unreliably genotyped samples 
and SNPs, population outliers as determined by 
multidimensional scaling of the genome-wide data, and 
samples for which there were sex discrepancies. The 
appendix details the samples excluded from every 
genome-wide dataset. 
The number of autosomal SNPs remaining for 
imputation were: 354 483 (GenOSept; Aﬀ ymetrix 5.0 
SNP array), 644 775 (GAinS; Illumina Human 
OmniExpressBeadChip SNP array), 936 437 (VASST; 
Illumina Human 1M-Duo BeadChip SNP array), and 
934 810 (PROWESS; Illumina Human 1M-Duo BeadChip 
SNP array). All GWAS datasets were imputed separately 
with IMPUTE2 and with 1000 Genomes Project data as a 
reference panel (ﬁ gure 1; appendix). 
Within the additional GAinS cohort, we genotyped the 
top 11 SNPs from the meta-analysis with p values lower 
than 1 × 10–⁵, together with additional SNPs in each 
association peak where possible (23 SNPs in total), using 
the Sequenom MassARRAY iPLEX system and high-
resolution melting curve analysis (HRMA; appendix). We 
also used HRMA to genotype the top associated SNP 
rs4957796 in the whole GenOSept/GAinS discovery set to 
conﬁ rm the accuracy of imputation. DNA was not 
available for further genotyping in the VASST and 
PROWESS cohorts.
Statistical analyses 
Statistical power to detect an association with 28 day 
survival from sepsis due to pneumonia with a 
conventional genome-wide signiﬁ cance p value threshold 
of 5 × 10–⁸ for various odds ratios (ORs) and minor allele 
frequencies is presented in the appendix. In the 
GenOSept/GAinS discovery cohort (cohort 1) we had 
80% power to detect an association if the eﬀ ect size was 
strong (OR >2) and the minor allele frequency of more 
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than 30%. When all cohorts were combined, the required 
OR was reduced to 1·6 with the same assumptions. To 
select the SNPs to be genotyped in the ﬁ nal cohort, we 
used a commonly used p value threshold of less than 
1×10–⁵ for suggestive evidence of association in the 
discovery cohort. With this less stringent p value 
threshold we had 80% power to detect the same OR of 
1·6 if the discovery cohorts were combined. We also 
analysed the two patient groups (sepsis due to pneumonia 
and intra-abdominal infections) together as a 
heterogeneous sepsis cohort (appendix).
We analysed imputed and directly genotyped autosomal 
variants from each of the genome-wide datasets separately 
using SNPTEST2, apart from the genotypes from the 
GenOSept and GAinS cohorts that we analysed together 
using SNPTEST2 because the protocols for these studies 
were identical. The mortality rates in these two cohorts 
were very similar (18·1% for GenOSept and 21·6% for 
GAinS). We tested SNPs passing quality control ﬁ lters 
(appendix) after genotype imputation for association with 
survival at 28 days using logistic regression in SNPTEST2, 
with age and the ﬁ rst four multidimensional scaling 
(MDS) components (generated exclusively in the patient 
data) as covariates. Age is known to be a strong 
determinant of mortality in patients with sepsis and MDS 
components (similar to principal components analysis) 
were used to avoid confounding due to population 
Figure 1: Patient cohorts, samples, genotyping, and analysis
SNP=single nucleotide polymorphism. HRMA=high-resolution melting curve analysis. QC=quality control. 
1770 patients (Aﬀymetrix 5.0 
SNP Array) in GenOSept
720 patients (Illumina Human 
1M-Duo) in PROWESS23,24
Cohort 1 (genome-wide) Cohort 2 (genome-wide) 
Cohort 4 (selected SNPs) 
Cohort 3 (genome-wide) 
288 patients (Illumina Human
 1M-Duo) in GAinS
632 patients (Illumina Human 
1M-Duo) in VASST22
58 samples excluded due 
to phenotype
1 sample excluded due 
 to phenotype
148 samples excluded due 
to phenotype
120 samples excluded due 
to phenotype
187 samples excluded due
 to genotyping QC
46 samples excluded due
to genotyping QC
123 samples excluded due
 to genotyping QC
193 samples excluded due 
to genotyping QC
1525 patients in GenOSept 
(794 with pneumonia)
354 483 SNPs
241 patients in GAinS 
(241 with pneumonia)
644 775 SNPs
361 patients in VASST22 
(217 with pneumonia)
936 437 SNPs
407 patients in PROWESS23,24 
(301 with pneumonia)
934 810 SNPs
Imputation (IMPUTE2) Imputation (IMPUTE2) Imputation (IMPUTE2) Imputation (IMPUTE2)
Association test (SNPTEST2) Association test (SNPTEST2) Association test (SNPTEST2)
Meta-analysis (5 888 277 imputed SNPs after QC)
1002 patients from GAinS
(538 with pneumonia)
22 SNPs genotyped with Sequenom
1 SNP genotyped with HRMA
 GenOSept and 
GAinS; discovery 
(cohort 1) 
VASST;22 
discovery 
(cohort 2)
PROWESS;23,24 
discovery 
(cohort 3) 
GAinS; 
additional 
(cohort 4)
Number 1766 361 407 1002
Deaths 328 (19%) 115 (32%) 129 (32%) 174 (17%)
Men 1055 (60%) 226 (63%) 247 (61%) 505 (50%)
Women 711 (40%) 135 (37%) 160 (39%) 497 (50%)
Age (mean) 63·1 62·2 63·1 63·8
Individuals with pneumonia 1035 (59%) 217 (60%) 301 (74%) 538 (54%)*
Deaths among patients with 
pneumonia
185 (18%) 74 (34%) 100 (33%) 106 (20%)
Acute lung injury 553/1744 (32%) ·· ·· ··
Deaths among patients with acute 
lung injury
138/553 (35%) ·· ·· ··
APACHE II score; median (range) 17 (2–44) 26 (10–49) 24 (10–50) 16 (3–41)
Pathogen identiﬁ ed† 626/1035 (60%) 176/217 (81%) 185/301 (61%) 242/538 (45%)
Gram-positive or Gram-negative 
bacterial infection‡
479/626 (77%) 136/176 (77%) 170/185 (92%) 174/242 (72%)
Gram-positive infection‡ 336/626 (54%) 111/176 (63%) 109/185 (59%) 118/242 (49%)
Gram-negative infection‡ 166/626 (27%) 55/176 (31%) 93/185 (50%) 61/242 (25%)
Viral infection‡ 34/626 (5%) 4/176 (2%) 0 36/242 (15%)
Data are n (%) unless otherwise speciﬁ ed. APACHE II=Acute Physiology and Chronic Health Evaluation II. HRMA=high-
resolution melting curve analysis. *525 individuals passed the quality control for FER rs4957796 HRMA genotyping. 
†Among all patients with sepsis due to pneumonia. ‡Among patients with sepsis due to pneumonia when pathogen 
was identiﬁ ed; sometimes more than one pathogen was identiﬁ ed. 
Table: Characteristics of patients included in the ﬁ nal analyses
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structure (see the appendix for further details about 
selection of covariates in the model). We used the same 
strategy in all discovery cohorts (GenOSept/GAinS, 
VASST, and PROWESS). We combined the association 
statistics (additive model) for each of 5 888 277 reliably 
imputed autosomal SNPs in a random-eﬀ ects meta-
analysis for 28 day survival in patients with sepsis caused 
by pneumonia (1553 individuals, of whom 359 died 
within 28 days of ICU admission) using PLINK. Loci with 
p values lower than the commonly used suggestive 
p value threshold of 1 × 10–⁵ in the meta-analysis were 
genotyped in the additional cohort (cohort 4) and tested 
for association with logistic regression using age as a 
covariate. As the traditional random-eﬀ ects meta-analysis 
has sometimes been considered too conservative,26 a post-
hoc meta-analysis of the top SNPs chosen for further 
genotyping was done using METASOFT. The results are 
strikingly similar and do not change our conclusions 
(data not shown). We used Cox regression models to 
assess the eﬀ ect of genotype on survival time, and we 
calculated likelihood ratios (the signiﬁ cance for the 
diﬀ erence between the model with and without the 
genotype). The appendix contains more details of the 
statistical methods.
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results 
In the meta-analysis of patients with sepsis caused by 
pneumonia, 11 loci were associated with 28 day survival 
with p values lower than 1 × 10–⁵ (ﬁ gure 2; appendix). The 
genomic control parameter λ did not imply inﬂ ation by 
population structure (appendix). We noted the most 
signiﬁ cant association with 28 day survival for a SNP in 
chromosome 5 (rs4957796) in an intron of the FER gene 
(Fps/Fes related tyrosine kinase; p discovery=9·7 × 10–⁸; 
OR 0·52 [95% CI 0·41–0·66]; ﬁ gures 2 and 3; appendix). 
Genotyping of the additional cohort strengthened the 
evidence for association (p combined=5·6 × 10–⁸; OR 0·56 
[0·45–0·69]). ORs were consistent across all cohorts 
(ﬁ gure 4). To exclude the possibility that the larger 
GenOSept/GAinS discovery cohort was driving the 
association, we repeated the meta-analysis for the FER 
rs4957796 SNP, excluding this cohort. The result for this 
analysis (OR 0·59 [0·45–0·77]; p=1·8 × 10–⁴) is consistent 
with the OR of 0·56 for all four cohorts combined.
Direct genotyping of the most strongly associated SNP 
rs4957796 in the GenOSept and GAinS discovery sample 
sets conﬁ rmed the accuracy of imputation (imputation 
concordance rate of 96·5% [95% CI 95·6–97·5]; 
imputation probability is taken into account in the 
association statistics). 
Figure 2: Manhattan plot for the meta-analysis of 28 day survival in patients with sepsis due to pneumonia 
(additive model)
SNPs with minor allele frequency higher than 2%, information value higher than 0·8, and Hardy-Weinberg 
equilibrium p higher than 1×10–¹⁰ are included (5 888 277 SNPs in total). The region including the FER gene is 
highlighted in red. 
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Figure 3: Regional association plot for the chromosome 5 locus (rs4957796) in the meta-analysis of 28 day 
survival in patients with sepsis due to pneumonia (additive model) 
Colours indicate the correlation (r² in CEU [Utah residents with northern or western European ancestry] 1000 
Genomes data) with the top SNP rs4957796. 
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The second locus that showed evidence of association 
in all four cohorts (rs79423885), although not achieving 
even the less conservative genome-wide signiﬁ cance 
threshold of p<5 × 10–⁷ (p combined=1·5 × 10–⁶; OR 1·89 
[1·46–2·45]; appendix), is located in chromosome 6, in a 
so-called gene desert without any annotated nearby 
functional elements (appendix). Genotyping the 
remaining SNPs in the additional cohort did not support 
an association (appendix).
The results of the meta-analysis of pneumonia and 
abdominal infections combined are shown in the 
appendix. None of these SNPs showed convincing 
evidence of association.
We used a Cox regression model to examine the 
additive eﬀ ect of FER SNP rs4957796 alleles on the rate 
of death in the ﬁ rst 28 days after ICU admission in the 
patients with sepsis due to pneumonia in all four 
cohorts. We used directly genotyped data when available 
(all individuals recruited to the GenOSept and GAinS 
studies were directly genotyped for the SNP rs4957796). 
Each allele reduced the mortality over 28 days by 44% 
(unadjusted hazard ratio for death 0·56 [95% CI 
0·46–0·70]; likelihood ratio (LR) test p=8·2 × 10–⁹; 
ﬁ gure 5A). The association remained highly signiﬁ cant 
after adjustment for age and stratiﬁ cation by cohort 
(appendix; hazard ratio 0·56 [95% CI 0·45–0·69]; LR 
test p=3·4×10–⁹), and no evidence against the 
assumption of proportional hazards was noted, 
conﬁ rming the validity of the Cox regression model 
(test of Schoenfeld residuals27 p=0·64). Considering the 
follow-up of GenOSept and GAinS patients to 6 months 
(all patients directly genotyped; ﬁ gure 5B), the eﬀ ect of 
genotype decreased with time, there being a signiﬁ cant 
interaction between the eﬀ ect of genotype and time 
(interaction LR test p=0·003, appendix). The decreased 
risk of death associated with the C allele was apparent 
in all four cohorts (appendix). Mortality was 9·5% in 
patients carrying the CC genotype, 15·2% in those 
carrying the TC genotype, and 25·3% in those carrying 
the TT genotype (appendix).
A causative pathogen was identiﬁ ed in 626 (60%) of 
1035 patients with pneumonia in the GenOSept/GAinS 
genome-wide dataset, 176 (81%) of 217 patients with 
pneumonia in VASST, and 185 (61%) of 301 patients with 
pneumonia in PROWESS, but only in 242 (45%) of 
538 patients with pneumonia in the additional GAinS 
cohort. We did a post-hoc analysis of the association 
between rs4957796 and 28 day survival in those with 
known bacterial infection to establish whether the 
protective eﬀ ect of the FER allele is aﬀ ected by the type of 
causative pathogen. The numbers were too small to allow 
meaningful subgroup analyses in relation to individual 
pathogens. When all the individuals in whom no 
causative organism was isolated and those with viral, 
fungal, yeast, and atypical infections were removed from 
the analysis, the OR for the association between SNP 
rs4957796 and 28 day survival was further reduced 
indicating a greater eﬀ ect size (appendix) and became 
signiﬁ cant in the additional GAinS cohort (p=0·047; 
OR=0·4, 95% CI 0·16–0·99).
Discussion
To our knowledge, this is the ﬁ rst genome-wide 
association study of survival in patients with sepsis 
treated in intensive care (panel). By studying four 
independent cohorts, we found that in patients with 
sepsis caused by pneumonia a common variant in the 
FER gene was signiﬁ cantly associated with 28 day 
survival. The most signiﬁ cantly associated SNP 
(rs4957796) is located in an intronic region of the FER 
gene and the minor allele is protective. The minor allele 
frequency was 10% in those who died and 19% in those 
who survived in our European dataset (cohort 1: 
GenOSept/GAinS) compared with a frequency of 21% 
in the European populations (CEU; Utah residents with 
northern and western European ancestry) in the publicly 
Figure 5: Cumulative percentage death rates in patients with sepsis caused 
by pneumonia according to FER rs4957796 genotype 
(A) All cohorts combined followed up until 28 days from ICU admission. (B) 
Directly genotyped GenOSept/GAinS discovery and additional GAinS cohorts 
followed up until 6 months from ICU admission.
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available 1000 Genomes Project data and 17% in the UK 
population in the publicly available 1000 Genomes 
Project data. The reduction in mortality associated with 
the minor allele is substantial; when all cohorts are 
combined, mortality decreases from about 25% in wild-
type homozygous (TT) patients to 15% in carriers of one 
copy of the minor C allele and is further reduced to 10% 
among individuals who are homozygous for the C allele. 
The survival curves indicate that, as might be expected, 
the protective eﬀ ect of this SNP is most evident in the 
acute phase of the illness. The ORs were strikingly 
consistent in all the cohorts examined, despite 
diﬀ erences in illness severity, suggesting that the 
association is robust and generalisable to the whole 
population of patients with pneumonia admitted to 
critical care units with sepsis. It is possible, however, 
that because of the lower mortality in the GenOSept/
GAinS discovery cohort some weaker associations 
might have been missed, but larger studies will be 
required to explore this possibility.
Importantly, this locus was identiﬁ ed only in the 
analysis of the group of patients with sepsis of pulmonary 
origin. Genetic associations with survival in pulmonary 
but not extrapulmonary infections have previously been 
identiﬁ ed using a candidate gene approach.28 The 
association also seemed to be stronger in patients with 
proven bacterial sepsis. Although the result in the 
additional cohort (cohort 4) was consistent with ﬁ ndings 
with the other cohorts and increased the signiﬁ cance of 
the combined analysis, the 95% CI of the association 
between rs4957796 and 28 day outcome in this cohort did 
cross 1 (appendix). This result is perhaps partly explained 
by the lower proportion of patients with proven bacterial 
infection in this cohort than that of the genome-wide 
datasets combined. Although the numbers were small, 
when only patients with proven bacterial infection were 
analysed, the association was signiﬁ cant in this additional 
cohort. These ﬁ ndings highlight the increasingly 
recognised importance of studying and tailoring 
treatment for homogeneous categories of patients with 
sepsis, both in terms of source of infection and also 
microbiological aetiology.
The FER gene encodes a non-receptor protein tyrosine 
kinase that acts downstream of cell-surface receptors for 
growth factors and is ubiquitously expressed.29 FER is 
known to have a role in the regulation of the actin 
cytoskeleton, cell adhesion, migration and invasion, and 
chemotaxis.30–33 FER inﬂ uences leucocyte recruitment and 
intestinal barrier dysfunction in response to bacterial 
lipopolysaccharide,34,35 ﬁ ndings relevant to the potential 
mechanisms by which variants in this gene could 
inﬂ uence sepsis survival. Furthermore, studies in mice 
targeted with a FER kinase-inactivating mutation have 
shown that FER can inhibit neutrophil chemotaxis.36 
Neutrophil recruitment to the site of infection is essential 
in innate immune defence and changes in relevant 
signalling pathways could lead to a failure to clear bacterial 
infections or could promote further tissue damage.37 
Although the most signiﬁ cantly associated SNP is located 
in the intronic region of FER, the region of association 
spans several coding exons. Further functional studies, for 
example the study of FER rs4957796 allele-speciﬁ c cellular 
responses to endotoxin and cytokine stimulation, will be 
required to elucidate the role of FER in sepsis and the 
mechanisms by which polymorphisms in this gene could 
aﬀ ect survival, but are beyond the scope of this study.
The second locus (rs79423885 in chromosome 6) that 
showed suggestive evidence of association with 28 day 
survival did not achieve even the less stringent genome-
wide signiﬁ cance level of 5 × 10–⁷, although the eﬀ ect 
sizes were consistent in all four independent cohorts. 
Larger sample sets will be needed to conﬁ rm or refute 
this association. Because this SNP is located in a gene 
desert, not in close proximity to the MHC region, and 
since no functional elements for this locus have been 
identiﬁ ed from the ENCODE data or other publicly 
available databases, the clinical implications of this 
ﬁ nding are unclear.
Previous candidate gene association studies in sepsis 
phenotypes have often been limited by the restricted 
number of loci examined and reliance on existing 
biological hypotheses. Moreover, failure to replicate 
Panel: Research in context
Systematic Review
We searched PubMed for genome-wide association studies 
(GWAS) of sepsis related phenotypes by using search words 
“genome wide association study” and “sepsis”. By Sept 23, 
2014, no GWAS of adult sepsis susceptibility or survival had 
been published. We found one GWAS of treatment response 
in patients with sepsis.24  
Interpretation
This is the ﬁ rst genome-wide association study of sepsis 
survival to be reported as far as we are aware. Because 
recruiting large, homogeneous, cohorts of sepsis patients is 
diﬃ  cult, we used genotyping data from four independent 
cohorts to identify common variants in the FER gene that 
associate with a reduced risk of death from sepsis due to 
pneumonia. The eﬀ ect of the most signiﬁ cantly associated 
variant in FER, rs4957796, is unusually strong: when patients 
are stratiﬁ ed based on genotype, mortality decreases from 
about 25% in wild-type homozygous (TT) patients to 15% in 
carriers of one copy of the minor C allele and is further 
reduced to 10% in individuals who are homozygous for the C 
allele. In view of the high allele frequency and large eﬀ ect 
size of this SNP, the population attributable protection 
aﬀ orded by FER variants is substantial. Because many of the 
functions of FER and its associated biological pathways are 
important in host defence, this ﬁ nding suggests potentially 
productive new avenues for sepsis research, including the 
identiﬁ cation of novel targets for treatment or prevention 
and the development of biomarkers for risk stratiﬁ cation.
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positive ﬁ ndings has been a common experience, 
especially when investigating associations with sepsis 
outcomes.17,18,38 Possible explanations include low 
statistical power, heterogeneous patient populations, 
and imprecise deﬁ nition of phenotypes.39 More recently 
the GWAS approach has identiﬁ ed variants in the 
complement factor H region that associate with 
susceptibility to meningococcal disease in children,40 
and in adult trauma victims to suggest that PPFIA1 
might be a functional candidate risk gene for acute lung 
injury.41 Another recent study used a genotyping panel 
that included more than 48 000 markers associated with 
cardiovascular, metabolic, and inﬂ ammatory syndromes42 
to identify an association between SNPs in the BCL2 and 
SERPINA4 genes and a decreased risk of developing 
sepsis-related acute kidney injury. By contrast with the 
present study, which focused on sepsis outcome, these 
investigators report40–42 associations with susceptibility to 
speciﬁ c infections or the risk of developing a particular 
organ failure.
We have identiﬁ ed a common variant in the FER gene 
that is strongly associated with protection from death in 
patients with sepsis caused by pneumonia. In view of the 
high allele frequency and large eﬀ ect size of this SNP, 
the population attributable protection aﬀ orded by the 
FER variant is substantial. FER encodes a cytosolic non-
receptor tyrosine kinase that inﬂ uences neutrophil 
chemotaxis and endothelial permeability. Because many 
of the functions of FER and its associated biological 
pathways are important in host defence this ﬁ nding 
suggests potentially productive new avenues for sepsis 
research, including the identiﬁ cation of novel targets for 
therapy or prevention and the development of biomarkers 
for risk stratiﬁ cation. 
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